Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
Pichler
R
R
Maschek
W
W
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism*; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000008:administration & dosage; D005260:Female; D006801:Humans; D010456:Peptides, Cyclic / Q000008:administration & dosage; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013972:Thyrotropin / Q000378:metabolism*; D013997:Time Factors
D000970:Antineoplastic Agents; D004873:Ergolines; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D013972:Thyrotropin; D000077465:Cabergoline